biotech.today

Details

  • ●Modalities: small molecules, biologics, cell therapies, antisense oligonucleotides
  • ●Therapeutic areas: oncology, neuroscience, metabolic diseases, infectious diseases, fibrosis
  • ●Key targets: multi-target across 15+ therapeutic areas
  • ●Indications: Alzheimer's disease, diabetes, kidney disease, anti-infectives
  • ●Funding: Public (€800M+ revenue, FY2023)

Partners & investors

  • Public (Frankfurt: EVT)· Investor
  • Mubadala Investment Company· Investor
  • T. Rowe Price· Investor

Key considerations

  • ●AI tools in use: EVOpanOmics (multi-omics platform), PanHunter (target discovery AI), Just – Evotec Biologics (AI-driven biologics CDMO), High-content screening + robotics
  • ●Triple-digit million EUR AI/platform investment (2024-2026)
  • ●150+ pharma/biotech partnerships
  • ●Bayer strategic partnership (iPSC, CKD)

Pipeline

  • Phase 11
  • Phase 21
Get live updates on Evotec SE’s hiring, filings, and partnerships. Follow in BT Pro →
Source: Company website, SEC / Companies House filings, press releases, Crunchbase · biotech.today analysis (Apr 2026)

Key people

Christian Wojczewski

CEO (interim, from Jan 2024)

pharma operationsbusiness development
Visit website →LinkedIn →